LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study

BACKGROUND: Respiratory syncytial virus (RSV) represents an important global health challenge with significant morbidity and mortality in infants, elderly, and immunocompromised adults. No effective therapy is currently available. EDP-938 demonstrates potent in vitro activity against RSV Subtypes A...

Descripción completa

Detalles Bibliográficos
Autores principales: Coakley, Eoin, Ahmad, Alaa, Larson, Kajal, McClure, Ty, Lin, Kai, Tenhoor, Kursten, Eze, Kingsley, Noulin, Nicolas, Horvathova, Veronika, Murray, Bryan, Baillet, Mark, Mori, Julie, Adda, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810094/
http://dx.doi.org/10.1093/ofid/ofz415.2489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810094/
http://dx.doi.org/10.1093/ofid/ofz415.2489

Ejemplares similares